SomaLogic announces new agreement with Amgen to accelerate drug discovery and development efforts through comprehensive proteomic profiling
SomaLogic, Inc. announced today an agreement with Amgen that will use SomaLogic’s proprietary proteomics technology to help advance Amgen’s drug discovery and development programs. The agreement builds upon SomaLogic’s existing collaboration with deCODE genetics, an Amgen subsidiary based in Iceland, and will include broader application across Amgen’s pipeline.
Sign up to receive our news releases
Protein-genotype associations (pQTLs) are an important tool for identifying proteins that link genetic variants with disease states. On August 6, 2020, Dr. Benjamin Sun will discuss how he and his colleagues at the University of Cambridge used the SomaScan® Assay to develop a pQTL atlas for the human plasma proteome.
More SomaLogic News
SomaLogic, Inc. and NEC Solution Innovators, Ltd. of Japan, a subsidiary of NEC Corporation, announced today the establishment of FonesLife Corporation, a new Tokyo-based company that will bring a series of new clinical health management tests based on SomaLogic’s proprietary protein-measurement technology to the Japanese people.
At SomaLogic, we measure proteins in the human body, and derive important health insights from that information for each individual. Depending on the day, the expression of these proteins in each individual human body can vary significantly, and we analyze this variability to discern patterns that may predict current conditions or future disease. But however variable the expression may be, we also know that the identity of every individual’s proteins are the same, regardless of skin color, country of origin, gender, religious preference or socioeconomic status. We always measure these proteins the same way because we know there is only one species of human beings.
Today SomaLogic, Inc. announced an enhanced collaboration with NEC Solution Innovators, Ltd. of Japan, a subsidiary of NEC Corporation, that builds on the companies’ ten-year partnership by bringing new clinical tests based on SomaLogic’s proprietary protein-measurement technology to the Japanese population.
SomaLogic announced today that it has added a new set of four research use only (RUO) SomaSignal™ tests that can diagnose all four components of non-alcoholic steatohepatitis (NASH) without the need for an invasive liver biopsy.
WEBINAR: What Can Proteomics Teach Us About Infectious Disease?
On June 25, 2020, Kevin Coombs of the University of Manitoba described his work using the SomaScan Assay to identify biological processes associated with infection by Zika virus and various strains of influenza. He also discussed how the SomaScan Assay could be used to further study infectious disease, including the current COVID-19 pandemic, in the immediate future.
WEBINAR: Plasma Proteins as Comprehensive Indicators of Health
On May 12, 2020, Stephen Williams (SomaLogic), Claudia Langenberg (University of Cambridge), and Peter Ganz (UCSF) discussed their recent proof-of-concept study that illustrated how measuring blood proteins at scale could lead to a future comprehensive “liquid health check.” They also explored the implications of their findings for public health, particularly in the areas of diabetes and cardiovascular disease.
WEBINAR: The Liquid Liver Biopsy: Characterizing NASH and NAFLD with Serum Protein Biomarkers
On April 30, 2020, Dr. Steve Williams, Chief Medical Officer for SomaLogic, discussed how the SomaScan Assay can noninvasively and simultaneously predict all the key elements of the liver biopsy: liver fat, inflammation, hepatocyte ballooning and fibrosis based only on serum protein biomarkers.
WEBINAR: Proteomics the Missing Link between GWAS, EWAS and Disease Endpoints
On April 8, 2020, Karsten Suhre, Director of the Bioinformatics Core at Weill Cornell Medicine-Qatar, discussed how the SomaScan Assay can complement genome-wide association studies (GWAS) and epigenome-wide association studies (EWAS) to link genetic variants and DNA methylation patterns to disease endpoints.
WEBINAR: Aging and the Proteome, or How to Die Young at a Very Old Age
On March 4, 2020, Nir Barzilai, Director of the Institute for Aging Research at Albert Einstein College of Medicine and Benoit Lehallier, Instructor in Neurology at Stanford University, discussed the findings of their Nature Medicine paper “Undulating changes in human plasma proteome profiles across the lifespan” and presented new data exploring how probing the proteome can help us to separate chronological age from biological age.
SomaScan proteomic technology is now broadly available to COVID-19 researchers and drug developers to expand and accelerate response to the pandemic
SomaLogic today launched a new initiative to deploy their proteomic technology against the coronavirus pandemic. The company is making its proprietary SomaScan® Assay available to biopharma companies, academic medical investigators, and government entities working on COVID-19/SARS-CoV-2 infection under simplified terms, with data from non-pharma studies to be shared rapidly and widely.
SomaLogic announced today that it has launched three additional SomaSignal™ tests to further empower individuals to manage their state of health more effectively. These new blood-based tests measure glucose tolerance, visceral fat and resting energy rate.
For older news and press releases, please visit our archive.